Last reviewed · How we verify

Naloxone HCl intranasal

Purdue Pharma LP · Phase 2 active Small molecule

Naloxone HCl intranasal is a Small molecule drug developed by Purdue Pharma LP. It is currently in Phase 2 development. Also known as: Narcan.

At a glance

Generic nameNaloxone HCl intranasal
Also known asNarcan
SponsorPurdue Pharma LP
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Naloxone HCl intranasal

What is Naloxone HCl intranasal?

Naloxone HCl intranasal is a Small molecule drug developed by Purdue Pharma LP.

Who makes Naloxone HCl intranasal?

Naloxone HCl intranasal is developed by Purdue Pharma LP (see full Purdue Pharma LP pipeline at /company/purdue-pharma-lp).

Is Naloxone HCl intranasal also known as anything else?

Naloxone HCl intranasal is also known as Narcan.

What development phase is Naloxone HCl intranasal in?

Naloxone HCl intranasal is in Phase 2.

Related